Margaret Horn Net Worth

The estimated Net Worth of Margaret A Horn is at least $12.3 Milhão dollars as of 17 June 2024. Ms. Horn owns over 4,415 units of Revolution Medicines Inc stock worth over $5,692,881 and over the last 5 years she sold RVMD stock worth over $4,440,864. In addition, she makes $2,215,110 as Chief Operating Officer e General Counsel at Revolution Medicines Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Horn RVMD stock SEC Form 4 insiders trading

Margaret has made over 24 trades of the Revolution Medicines Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 4,415 units of RVMD stock worth $165,077 on 17 June 2024.

The largest trade she's ever made was selling 70,000 units of Revolution Medicines Inc stock on 1 October 2020 worth over $2,455,600. On average, Margaret trades about 8,313 units every 42 days since 2020. As of 17 June 2024 she still owns at least 136,651 units of Revolution Medicines Inc stock.

You can see the complete history of Ms. Horn stock trades at the bottom of the page.

Margaret Horn biography

Margaret A. Horn J.D. serves as Chief Operating Officer, General Counsel of the Company. Peg initially studied pharmacy, but shortly into that five-year educational program decided to advance her education by attending either medical or law school. A lawyer-professor at her pharmacy school tailored an independent legal study course for her, sealing her fate. She completed pharmacy school and then studied law at Villanova Law School. While still in law school, she worked part-time in DuPont’s legal department and subsequently joined the company counseling its pharmaceutical division. During her tenure there, she set a pharmaceutical division record for most patent applications filed in one month (12). Led by an entrepreneurial spirit and a desire to see more of the country, she moved to San Francisco. Once there, she embarked on a 25-year adventure in biotechnology, working at both large/public companies (Genencor International and Kosan Biosciences) and small, privately held companies (Cogentus and ProLynx). Through years of corporate experience, international business transactions and worldwide litigation, Peg’s role evolved from patent counsel to general counsel and secretary. At Genencor, she led the legal effort for its IPO (in 2000) and later a multiparty M&A process that resulted in the company’s privatization and acquisition by a multinational conglomerate. Throughout her career, Peg has held multiple senior vice president positions in legal, business and corporate development. Peg holds a B.S. in pharmacy and a J.D., as well as an executive M.B.A. She is a member of the Pennsylvania and California bars and is a registered patent attorney with the U.S. Patent & Trademark Office. She is a registered pharmacist in Pennsylvania.

What is the salary of Margaret Horn?

As the Chief Operating Officer e General Counsel of Revolution Medicines Inc, the total compensation of Margaret Horn at Revolution Medicines Inc is $2,215,110. There are 1 executives at Revolution Medicines Inc getting paid more, with Mark Goldsmith having the highest compensation of $4,576,250.

How old is Margaret Horn?

Margaret Horn is 56, she's been the Chief Operating Officer e General Counsel of Revolution Medicines Inc since 2019. There are 10 older and 7 younger executives at Revolution Medicines Inc. The oldest executive at Revolution Medicines Inc is Elizabeth Anderson, 62, who is the Independent Director.

What's Margaret Horn's mailing address?

Margaret's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Revolution Medicines Inc

Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder, eRock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.

What does Revolution Medicines Inc do?

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Complete history of Ms. Horn stock trades at Sangamo Therapeutics Inc e Revolution Medicines Inc

Revolution Medicines Inc executives and stock owners

Revolution Medicines Inc executives and other stock owners filed with the SEC include:

• Mark Goldsmith,
  Chairman of the Board, President, Chief Executive Officer
• Margaret Horn,
  Chief Operating Officer, General Counsel
• Steve Kelsey,
  President of Research and Development
• Dr. Mark A. Goldsmith Ph.D.,
  CEO, Pres & Chairman
• Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.,
  Pres of R&D
• Margaret A. Horn J.D.,
  COO, Gen. Counsel & Sec.
• Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.,
  Pres of R&D
• Margaret A. Horn,
  COO, Gen. Counsel & Sec.
• Xiaolin Wang,
  Exec. VP of Clinical Devel.
• Dr. Mark A. Goldsmith M.D., Ph.D.,
  CEO, Pres & Chairman
• Alexis Borisy,
  Lead Independent Director
• Barbara Weber,
  Independent Director
• Vincent Miller,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Peter Svennilson,
  Independent Director
• Thilo Schroeder,
  Independent Director
• Eric Schmidt,
  Independent Director
• Neil Exter,
  Independent Director
• Jack Anders,
  Vice President - Finance and Principal Accounting Officer
• Dr. Martin D. Burke M.D., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Jack Anders,
  Sr. VP of Fin. & Principal Accounting Officer
• Luan M. Wilfong,
  Sr. VP of HR
• Walter Reiher Ph.D.,
  Chief Information Officer
• David L. Pompliano,
  Founding Chief Scientific Officer
• Dr. Kevan M. Shokat,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Michael A. Fischbach,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Martin D. Burke,
  Co-Founder & Chairman of Scientific Advisory Board
• Frank Clyburn,
  
• Group Iii, Lpcolumn Group I...,
  
• Laurence Lasky,
  Director
• Group Iii, Lp Svennilson Pe...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iv, L.P.Third...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Lin Wei,
  Chief Medical Officer
• Jeff Cislini,
  General Counsel
• Stephen Michael Kelsey,
  See Remarks
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Xiaolin Wang,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Sushil Patel,
  
• Flavia Borellini,
  
• Lorence H. Kim,